Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.5 USD | -6.25% | -1.10% | -26.25% |
Apr. 22 | Trupanion Introduces truInsights: A Pet Health Data Initiative | CI |
Apr. 05 | Piper Sandler Cuts Price Target on Trupanion to $28 From $32, Maintains Overweight Rating | MT |
Strengths
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-26.25% | 945M | C | ||
+13.03% | 9.62B | B- | ||
-3.09% | 6.37B | C+ | ||
+14.44% | 5.96B | C | ||
+89.84% | 4.11B | - | ||
-2.30% | 2.35B | B+ | ||
+2.95% | 868M | - | D+ | |
+88.89% | 762M | - | C | |
+5.81% | 159M | - | - | |
-7.41% | 69.23M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TRUP Stock
- Ratings Trupanion, Inc.